drug_type
RELEVANT_DRUG
intervention_type
Small molecule (EGFR tyrosine kinase inhibitor)
drug_description
Aumolertinib (HS-10296; almonertinib) is an oral, third-generation, irreversible EGFR tyrosine kinase inhibitor selective for activating EGFR mutations, inhibiting downstream MAPK and PI3K/AKT signaling.
nci_thesaurus_concept_id
C133691
nci_thesaurus_preferred_term
Aumolertinib
nci_thesaurus_definition
An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
drug_mesh_term
Aumolertinib
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
Third-generation, irreversible EGFR tyrosine kinase inhibitor selective for mutant EGFR (e.g., Ex19del, L858R, T790M). Covalently inhibits EGFR kinase activity, blocking autophosphorylation and downstream MAPK and PI3K/AKT signaling, resulting in growth inhibition and apoptosis of EGFR-mutant tumor cells.
drug_name
Aumolertinib
nct_id_drug_ref
NCT06417008